Segment Information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Information

Note 17. Segment Information

We operate in one operating segment, and therefore one reportable segment, focused on the global discovery, development and commercialization of proprietary therapeutics. We manage business activities on a consolidated basis through the development and commercialization of oncology and dermatology products, which are sold to U.S. and international customers. Our determination that we operate as a single operating segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker is the Chief Executive Officer.

The accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies. Our single operating segment generates revenues from the development and commercialization of oncology and dermatology pharmaceutical products, which are developed by our research and development department, as well as from product royalties, milestone and contract revenues from the out-licensing of our intellectual property to third parties.

For our segment, the chief operating decision maker uses net income or loss, that also is reported on the consolidated statements of operations as consolidated net income (loss), to allocate resources (including employees, property, and financial resources), predominantly during the annual budget and forecasting process. The chief operating decision maker also uses consolidated net income or loss, along with non-financial inputs and qualitative information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment in our various operating activities and other capital allocation activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets.

Net income for our segment was as follows (in thousands):

	Year Ended December 31,
	2024		2023		2022
Product revenues, net	$	3,618,888	$	3,165,168	$	2,746,897
Product royalty revenues	579,329		523,481		482,738
Milestone and contract revenues	43,000		7,000		165,000
Total revenues	4,241,217		3,695,649		3,394,635
Costs, expenses and other:
Cost of product revenues (including definite-lived intangible amortization)	312,068		254,990		206,997
Research and development - internal1	957,043		815,025		739,785
Research and development - external2	866,005		775,919		720,201
Other research and development3	783,800		36,650		125,950
Sales and marketing	945,428		876,703		770,141
General and administrative	296,729		284,590		231,999
Loss on change in fair value of acquisition-related contingent consideration	19,803		29,202		12,149
(Profit) and loss sharing under collaboration agreements	(1,025)		2,045		7,973
Other segment items4	28,751		22,926		238,780
Net income	$	32,615	$	597,599	$	340,660

1.Research and development - internal is comprised of internally generated costs such as salaries, travel, regulatory costs, lab costs, contracting, etc.

2.Research and development - external is comprised of specific program spend with external vendors (i.e. contract manufacturing organization, contract research organization and lab vendors for clinical, technical operations and toxicology services).

3.Other research and development is comprised of all other costs including certain one-time costs resulting from the acquisition of IPR&D assets and one-time development milestone expenses.

4.Other segment items is comprised of interest income, interest expense, realized and unrealized (gain) loss on equity investments, other, net, and provision for income taxes.

During the year ended December 31, 2024, total revenues generated by subsidiaries in the United States was approximately $4.0 billion, total revenues generated from subsidiaries in Europe was approximately $260.4 million, and total revenues generated from subsidiaries in other countries was approximately $6.2 million. During the year ended December 31, 2023, total revenues generated by subsidiaries in the United States was approximately $3.5 billion, total revenues generated from subsidiaries in Europe was approximately $175.9 million, and total revenues generated from subsidiaries in other countries was approximately $4.9 million. During the year ended December 31, 2022, total revenues generated by subsidiaries in the United States was approximately $3.2 billion and total revenues generated from subsidiaries in Europe was approximately $147.0 million.

As of December 31, 2024, property and equipment, net was approximately $474.1 million in the United States, approximately $277.6 million in Switzerland and approximately $11.7 million in other countries. As of December 31, 2023, property and equipment, net was approximately $432.3 million in the United States, approximately $303.9 million in Switzerland and approximately $15.3 million in other countries.